The authors wish to bring to the readers' attention typographical error identified in Supplementary Table 2 with the online version of the article showing the dose constraints guidance used for 3D conformal planning for total prescription dose of 36Gy in 6 fractions (1). The content of the columns for other bowel were inadvertently moved in formatting. This was not recognized by the authors at the time of manuscript review. The corrected Supplementary Table 2 is as below. We apologize for any inconvenience.
Supplementary Table 2.
Dose constraints guidance used for 3D conformal planning for total prescription dose of 36Gy in 6 fractions
| Organ | Constraint | ||
|---|---|---|---|
| Rectum (including anus) |
17Gy | 80% | |
| 28Gy | 60% | ||
| 33Gy | 50% | ||
| 36Gy | 30% | ||
| Femoral heads | 28Gy | 50% | |
| Other bowel (including small and large bowel as a single structure) |
optimal | mandatory | |
| V25 | 139cc | 208cc | |
| V28 | 122cc | 183cc | |
| V31 | 105cc | 157cc | |
| V33 | 84cc | 126cc | |
| V36 | 26cc | 39cc | |
Proposed constraints are based on total prescription dose of 36Gy prescribed to 100% at the International Commission on Radiation Units and Measurements reference point. In those with advanced disease or limited performance status 30Gy in 5 fractions was considered (three patients planned to 30Gy in 5 fractions). Dose constraints were derived from previously recruited phase III studies (CHHIP and BC2001) using linear quadratic model assuming α/β of 10 for tumor control and 3 for normal tissue 2, 3, 4, 5. Organs at risk were contoured as solid structures by defining their outer wall on CT0. Other bowel constraints were specified only for the small plan and medium plan as it was expected that the large plan would exceed above constraints given the position of bowel on the planning CT scan is not reflective of true bowel position at treatment delivery when large plan would be selected for treatment.
References
- 1.Hafeez S., McDonald F., Lalondrelle S. Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys. 2017;98:115–122. doi: 10.1016/j.ijrobp.2017.01.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.James N.D., Hussain S.A., Hall E. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–1488. doi: 10.1056/NEJMoa1106106. [DOI] [PubMed] [Google Scholar]
- 3.Dearnaley D., Syndikus I., Sumo G. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13:43–54. doi: 10.1016/S1470-2045(11)70293-5. [DOI] [PubMed] [Google Scholar]
- 4.Pos F.J., Hart G., Schneider C. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys. 2006;64:1168–1173. doi: 10.1016/j.ijrobp.2005.09.023. [DOI] [PubMed] [Google Scholar]
- 5.McDonald F., Waters R., Gulliford S. Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol (R Coll Radiol) 2015;27:22–29. doi: 10.1016/j.clon.2014.09.016. [DOI] [PubMed] [Google Scholar]